VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager (“BiTAC(R)-TCE”) program, marking another step in preparing the company’s most advanced oncology candidate for future clinical development.
The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to support manufacturing, analytical development, and nonclinical studies required before clinical testing.
This partnership represents an important development milestone for VERAXA as it advances its lead BiTAC(R) program toward IND/CTA-enabling studies. The BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches. By engineering more precise T-cell engagement, the platform aims to enhance therapeutic efficacy while minimizing off-target effects, a common challenge in cancer immunotherapy.
VERAXA recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development. The expansion underscores the company’s commitment to advancing its pipeline, which includes several candidates targeting solid tumors.
The selection of ATUM for cell line development leverages the Leap-In Transposase(R) technology, which enables efficient and stable integration of genetic material into host cells, facilitating the generation of high-yield, stable clonal cell lines. This is critical for producing consistent, high-quality material for nonclinical studies and eventual clinical trials.
For investors, the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. VERAXA Biotech is positioning itself as a key player in the next generation of T-cell engagers, with a focus on reducing toxicity while maintaining potent anti-tumor activity. The successful advancement of its lead candidate could address significant unmet needs in oncology, particularly for patients with solid tumors that are resistant to current immunotherapies.
As the company progresses toward clinical development, the collaboration with ATUM provides a foundation for scalable manufacturing and robust analytical methods, essential for regulatory submissions and eventual commercialization. The BiTAC(R) platform’s potential to improve selectivity may also open doors to combination therapies and broader patient populations.
